"It’s just this amazing thing when a peer throws the gauntlet down like that,“ the two-time Grammy winner said in reference ...

Orphan drug specialist Amicus Therapeutics is paying Dimerix $30 million cash for U.S. rights to the phase 3 prospect DMX-200 ...

Good morning! Here’s everything you need to know, and some things you don't, before the ASX flings open its doors and begins trading today.

Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and ...

Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatmentof Focal Segmental Glomerulosclerosis (FSGS) ...

A powerful showing by Australian tech stocks has pulled the ASX out of the red to post a 0.24pc gain ... Read More The post ...